|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Lung Cancers Overview - Intensive R&D activity but little improvement in patient outcomes
Datamonitor, Dec 2010, Pages: 167
Introduction
Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) remains poor. The late-phase pipeline holds little promise for considerable improvements in patient outcomes however; these drugs are forecast to realize sales of over $3.1 billion by 2019. Many unmet needs remain unfulfilled; therefore significant commercial opportunities exist.
Features and benefits
- Identify key drugs and companies within the lung cancers pipeline based on sales forecasts to 2019 and Datamonitor drug assessment
- Characterize unmet need and poorly served patient groups within lung cancer and assess the potential for pipeline products to fulfill them
- Assess the shifting lung cancer market dynamic and how future treatment will incorporate pipeline products
Highlights
- There are 134 drugs in development for non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Molecular targeted therapies constitute the bulk (73%) of the pipeline. By contrast, cytotoxic therapies and immunotherapeutic/immunomodulatory drugs (including therapeutic cancer vaccines) account for only 13% of the pipeline each.
- The treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) is characterized by a high level of unmet need, most notably for more effective therapies to improve patient survival. This, together with the large patient population, translates into a high commercial potential, which is driving extensive R&D activity.
- Within the pipeline, 84% of drugs are seeking approval for the treatment of NSCLC and 16% for SCLC. The greater interest in NSCLC is not surprising, given that this indication is not only characterized by a high level of unmet need but also from a large and growing patient population. Therefore, NSCLC has the greatest commercial potential.
Your key questions answered
- Examination of the lung cancers pipeline with in-depth clinical and commercial profiles of Phase III candidates
- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions
- Segmentation and analysis of the current lung cancers pipeline by developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
|
|
|
|
